Introduction {#sec1}
============

Diabetes mellitus is a global epidemic and the associated hyperglycemia can cause a range of macrovascular and microvascular complications, which consequently evoke various diseases. One of the major microvascular complications of diabetes is retinopathy, a leading cause of vision impairment and blindness in working age adults.[@bib1]^,^[@bib2] Retinal neovascularization and macular edema, hallmarks of diabetic retinopathy, are associated with decreased retinal perfusion and increased capillary fluid filtration caused by microvascular dysfunction.[@bib3] However, the precise mechanisms involved in circulatory dysregulation in diabetes remain unclear. Accumulating evidence indicates that vitreous humor and plasma levels of endothelin-1 (ET-1) are increased in diabetes, especially in patients with diabetic retinopathy.[@bib4]^,^[@bib5] The ET-1 peptide is a potent vasoconstrictor and its overproduction can contribute to the development of cardiovascular disorders, including remodeling, tissue inflammation, cell proliferation, and vasomotor dysfunction.[@bib4]^,^[@bib6]^−^[@bib11] Although elevated levels of ET-1 have been suggested to contribute to retinal pathophysiology,[@bib12]^,^[@bib13] the clinical impact of ET-1 on retinal microvascular function is incompletely understood.

In the retinal microcirculation, the arterioles play an important role in governing retinal blood flow distribution and perfusion through changes in their local vasomotor tone and overall resistance, respectively.[@bib14] In the early stage of diabetes, reduction of arteriolar endothelium-dependent vasodilator function without apparent structural changes in the retina has been demonstrated recently.[@bib15]^,^[@bib16] At the segment of retinal venules, changes in their resistance, that is, diameter, influence hydrostatic pressure and fluid homeostasis in upstream capillaries.[@bib17]^,^[@bib18] Constriction of retinal venous vessels leads to an increased retinal venous pressure, which could subsequently decrease retinal perfusion and promote capillary fluid filtration (i.e., edema) when compensatory or defense mechanisms are exhausted in the earlier stages of diabetes before the development of retinopathy. However, our understanding of factors directly affecting the vasomotor activity of retinal venules is seemingly limited to three studies in pigs,[@bib19]^--^[@bib21] which resemble human retinal morphology and structure.[@bib22]^,^[@bib23] Our previous study found that ET-1 causes marked constriction of porcine retinal venules through ET~A~ receptors (ET~A~Rs) and extracellular Ca^2+^ influx independent of L-type voltage-operated Ca^2+^ channels.[@bib20] We have also shown that hyperglycemia, a hallmark of diabetes, augments porcine venular constrictions to ET-1, U46619, and norepinephrine.[@bib21] However, there has been no study addressing whether ET-1 affects the vasomotor tone of human retinal venules under euglycemia or hyperglycemia. In the present study, we addressed these issues by examining the vasomotor response to ET-1 in human retinal venules isolated from eyes donated by patients undergoing enucleation. Because hyperglycemia is one of the major risk factors for the development of diabetic retinopathy,[@bib24]^,^[@bib25] we also investigated whether short-term exposure of human retinal venules to high glucose in vitro affects the vasoreactivity to ET-1. Furthermore, we compared the ET-1--induced constriction from human vessels with results from the pig, a potential large animal model for the study of retinal microvascular diseases.

Methods {#sec2}
=======

Human Subjects Study {#sec2-1}
--------------------

Retinal tissues were obtained, over a period of 4 years, from 1 male (81 years old) and 4 female patients (45, 62, 69, and 69 years old) undergoing enucleation because of ocular melanoma. The study was conducted after informed consent with approval from the Baylor Scott & White Health Institutional Review Board and followed the tenets of the Declaration of Helsinki. The clinical characteristics for the patients in this study are summarized in the [Table](#tbl1){ref-type="table"}. No retinal complications were observed on gross examination of the enucleated eyes except for ocular melanoma. Two patients (one male and one female) had type 2 diabetes along with primary hypertension and hyperlipidemia; one patient had primary hypertension; and one patient had hyperlipidemia. One patient had not been diagnosed with cardiovascular risk factors but was taking a nonsteroidal anti-inflammatory drug. Additional medications and supplements that were taken for the noted cardiovascular disease risk factors included nonsteroidal anti-inflammatory drugs (*n* = 2), statin (*n* = 1), krill or fish oil (*n* = 2), Ca^2+^ channel blocker (*n* = 1), centrally acting alpha-2 adrenergic receptor agonist (*n* = 1), alpha-1 adrenergic receptor antagonist (*n* = 1), noninsulin antidiabetic drugs (*n* = 2), angiotensin-converting enzyme inhibitor (*n* = 1), and angiotensin II type 1 receptor antagonist (*n* = 2). Immediately after enucleation, a large part of the posterior eye wall segment associated with the tumor was removed for histopathologic examination. The remaining posterior eye wall segment (including the attached retina) was transferred to a moist chamber on ice for microvessel isolation. Depending on the amount of available tissue, we were able to isolate one to four retinal vessels per eye specimen.

###### 

Clinical Characteristics of Patients

  Patient   Sex      Cardiovascular Diseases                               Medications and Supplements
  --------- -------- ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1         Female   Hyperlipidemia                                        Krill oil
  2         Female   Primary hypertension                                  Ca^2+^ channel blocker Central alpha-2 adrenergic receptor agonist
  3         Female   None                                                  Nonsteroidal anti-inflammatory drug
  4         Female   Hyperlipidemia Type 2 diabetes Primary hypertension   Noninsulin antidiabetic drug Angiotensin-converting enzyme inhibitor Angiotensin II type 1 receptor antagonist
  5         Male     Hyperlipidemia Type 2 diabetes Primary hypertension   Fish oil, statin, noninsulin antidiabetic drug Nonsteroidal anti-inflammatory drug Alpha-1 adrenergic receptor antagonist Angiotensin II type 1 receptor antagonist

The sex, cardiovascular diseases, and medications and supplements to treat these diseases are provided for the five patients who donated retinal tissue for the vascular studies.

Animal Preparation {#sec2-2}
------------------

All animal procedures were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Baylor Scott & White Institutional Animal Care and Use Committee. Domestic (Yorkshire) pigs (8--12 weeks old, 10--15 kg, 3 females and 17 males) purchased from Real Farms (San Antonio, TX) were sedated with Telazol (4--8 mg/kg, intramuscularly), anesthetized with 2% to 5% isoflurane, and intubated for eye harvesting as described previously.[@bib26]^,^[@bib27] The eyes were enucleated and immediately placed in a moist chamber on ice.

Isolation and Cannulation of Microvessels {#sec2-3}
-----------------------------------------

Techniques for identifying and isolating human and porcine retinal microvessels were similar to those used in our previous studies.[@bib20]^,^[@bib21]^,^[@bib28] Briefly, retinal venules (1.0--1.5 mm in length without side branches) were identified based on the dark red deoxygenated blood in the lumen and their thin vascular wall compared with the parallel arterioles containing bright red oxygenated blood and a thick vascular wall.[@bib20] Single venules were dissected from surrounding neural and connective tissues and then cannulated on each end with glass micropipettes containing physiologic saline solution (PSS) with 5 mM (approximately 90 mg/dL; control) D-glucose and 1% albumin.[@bib21] The hyperglycemic solution contained 25 mM (approximately 450 mg/dL; high glucose) D-glucose in PSS.[@bib15]^,^[@bib21] Osmolarity in the 25 mM D-glucose solution was balanced to 290 mOsm by reducing the NaCl concentration to avoid a hyperosmolarity effect.[@bib29] Vessels were pressurized to 5 cm H~2~O (4 mm Hg) intraluminal pressure without flow by two independent pressure reservoirs and the inner diameter was recorded using videomicroscopic techniques throughout the experiments.[@bib20]

Experimental Protocols {#sec2-4}
----------------------

Cannulated venules were bathed in control solution at 36° to 37°C to allow development (2 hours) of basal tone ([Fig. 1](#fig1){ref-type="fig"}). The vasomotor response to cumulative administration of ET-1 (1 pM to 1 nM; Bachem, Torrance, CA) was then evaluated.[@bib20]^,^[@bib21]^,^[@bib30] Retinal venules were exposed to each concentration of ET-1 until a stable diameter was established (about 10 minutes). Because of the possible tachyphylaxis effect of ET-1 as noted in retinal arterioles[@bib31] and the sustained vasoconstriction to ET-1 after washing out, only one concentration--response curve was evaluated in each vessel. In another series of studies, the role of ET~A~Rs in the retinal venular responses to ET-1 was evaluated after a 30-minute treatment of the vessel with ET~A~R antagonist BQ123 (1 µM).[@bib20]^,^[@bib30] An additional group of retinal venules from pigs and human patients without diabetes was exposed to a high glucose solution for 2 hours and its impact on vasomotor responses to ET-1 was examined. The effect of hyperglycemia and ET~A~R activation on venular constriction to ET-1 (0.1 nM) was evaluated after co-incubation of control or high glucose solution with BQ123 (1 µM) for 30 minutes.

![Experimental protocol for the study of isolated and pressurized retinal venules.](tvst-9-9-1-f001){#fig1}

Chemicals {#sec2-5}
---------

All drugs were obtained from MilliporeSigma (St. Louis, MO). ET-1 was dissolved in water and BQ123 was dissolved in ethanol.[@bib20]^,^[@bib30] Subsequent concentrations of these drugs were diluted in PSS. The final concentration of ethanol in the vessel bath was less than 0.1% by volume, which had no effect on vasoconstrictor responses or basal tone in vehicle control studies.

Data Analysis {#sec2-6}
-------------

At the end of each experiment, the vessel was relaxed with 0.1 mM sodium nitroprusside in EDTA (1 mM) Ca^2+^-free PSS to obtain its maximum diameter at 5 cm H~2~O intraluminal pressure. Diameter changes in response to ET-1 were normalized to the resting diameter and expressed as percentage changes in diameter. Data are reported as mean ± standard error of the mean, and *n* represents the number of vessels. The repeated measures two-way analysis of variance followed by Bonferroni multiple-range test was used to determine the significance of experimental interventions, as appropriate (GraphPad Prism, Version 6.0, GraphPad Software, La Jolla, CA). A *P* value of less than 0.05 was considered significant.

Results {#sec3}
=======

For the present study, a total of 14 human retinal venules from five patients were isolated with average maximum diameter of 68 ± 4 µm (range, 47--79 µm) at 5 cm H~2~O lumenal pressure. In the presence of normal (5 mM) glucose, the human vessels (seven vessels, one to two per patient) developed stable basal tone by constricting to about 88% of maximum diameter (resting and maximum diameters are provided in [Supplementary Fig. S1](#tvst-9-9-1_s001){ref-type="supplementary-material"}) within 2 hours at 36°C to 37°C. An image of a cannulated and pressurized human retinal venule is shown in [Figure 2](#fig2){ref-type="fig"}A. In the pig study, the average maximum diameters of retinal venules (six vessels, one per pig) in the presence of normal glucose was 106 ± 4 µm, and these vessels constricted to about 92% of maximum diameter (resting and maximum diameters are provided in [Supplementary Fig. S1](#tvst-9-9-1_s001){ref-type="supplementary-material"}). Administration of ET-1 caused constriction of both human and porcine retinal venules in a concentration-dependent manner ([Fig. 2](#fig2){ref-type="fig"}B). The threshold concentration of ET-1 for venular constriction was about 1 pM, and the vessels constricted to about 40% to 50% of their resting diameters at 1 nM for both species (see [Supplementary Fig. S2](#tvst-9-9-1_s001){ref-type="supplementary-material"} for individual vessel responses).

![Vasomotor response of isolated and pressurized human and porcine retinal venules to ET-1. (A) Representative image of an isolated human retinal venule cannulated with glass micropipettes and secured with ophthalmic sutures. The vessel was transferred to the stage of an inverted microscope and was allowed to develop basal tone (45 µm internal diameter) at 5 cm H~2~O intraluminal pressure. (B) Human (*n* = 7) and porcine (*n* = 6) venular diameters were recorded before (R, resting diameter) and after administration of ET-1.](tvst-9-9-1-f002){#fig2}

Incubation of both human ([Fig. 3](#fig3){ref-type="fig"}A) and porcine ([Fig. 3](#fig3){ref-type="fig"}B) retinal venules with ET~A~R antagonist BQ123 in the presence of normal glucose did not alter the resting vascular diameter but ET-1--induced vasoconstrictions were abolished (see [Supplementary Fig. S3](#tvst-9-9-1_s001){ref-type="supplementary-material"} for individual vessel responses). The individual responses of vessels from three human patients (without diabetes) to ET-1 after normal or high glucose (25 mM) exposure are shown in [Figures 4](#fig4){ref-type="fig"}A to [4](#fig4){ref-type="fig"}C. In each patient, ET-1 produced concentration-dependent venular constrictions under normal level of glucose.

![Contribution of ET~A~Rs to ET-1--induced constriction of isolated and pressurized human and porcine retinal venules. (A) Human and (B) porcine venular diameters were recorded before (R, resting diameter) and after 30-minute treatment (T) with ET~A~R antagonist BQ123 (1 µM). In the absence of BQ123, retinal venules constricted in response to ET-1 in a concentration-dependent manner (human control, *n* = 3; porcine control, *n* = 4). Treatment with BQ123 (1 µM; BQ123 - human, *n* = 3; BQ123 - pig, *n* = 4) abolished venular constrictions to ET-1. \**P* \< 0.05 vs. control.](tvst-9-9-1-f003){#fig3}

![Impact of hyperglycemia on ET-1--induced constriction of isolated and pressurized human retinal venules. Venular diameters were recorded before (R, resting diameter) and after administration of ET-1 in the presence of control normal glucose (5 mM) or high glucose (25 mM). (A--C) Individual responses of human retinal venules isolated from three patients (A, 1 control vessel and 1 high glucose vessel; B, 2 control vessels and 2 high glucose vessels; C, 2 control vessels and 1 high glucose vessel). (D) Vasoconstrictions to ET-1 were significantly greater after 2 hours of intraluminal exposure to high glucose (control, *n* = 5; high glucose, *n* = 4). \**P* \< 0.05 vs. control.](tvst-9-9-1-f004){#fig4}

Under high glucose exposure for 2 hours, the resting vascular tone was not noticeably altered, but the constriction of retinal venules to ET-1 was consistently augmented in each patient ([Figs. 4](#fig4){ref-type="fig"}A--[4](#fig4){ref-type="fig"}C). The averaged responses to ET-1, in the presence of normal and high glucose, are shown in [Figure 4](#fig4){ref-type="fig"}D. Exposure of porcine retinal venules to high glucose enhanced vasoconstrictions to ET-1 ([Fig. 5](#fig5){ref-type="fig"}A) in a manner comparable with those of human vessels (see [Supplementary Fig. S4](#tvst-9-9-1_s001){ref-type="supplementary-material"} for individual vessel responses). The constriction of porcine retinal venules to 0.1 nM ET-1 during exposure to control normal glucose or high glucose was prevented in the presence of BQ123 ([Fig. 5](#fig5){ref-type="fig"}B).

![Impact of hyperglycemia and ET~A~R activation on ET-1--induced constriction of isolated and pressurized porcine retinal venules. Venular diameters were recorded before (R, resting diameter) and after administration of ET-1 in the presence of control normal glucose (5 mM) or high glucose (25 mM). (A) Vasoconstrictions to ET-1 were significantly greater after 2 hours of intraluminal exposure to high glucose (control, *n* = 4; high glucose, *n* = 4). \**P* \< 0.05 vs. control. (B) The vasoconstriction to 0.1 nM ET-1 during exposure to control (*n* = 4) or high glucose (*n* = 4) was abolished in the presence of ET~A~R antagonist BQ123 (1 µM). \**P* \< 0.05 vs. control; ^\#^*P* \< 0.05 vs. ET-1.](tvst-9-9-1-f005){#fig5}

Discussion {#sec4}
==========

It is generally accepted that the vasomotor activity of venules in the microcirculation plays an important role in the regulation of tissue perfusion and fluid homeostasis by influencing the longitudinal pressure gradient and postcapillary pressure, respectively.[@bib17] Alterations in this regulatory process may link to retinal pathophysiology, including retinal edema and diminished retinal perfusion. However, there is limited information regarding the vasomotor function of individual retinal venules, especially the responses of human retinal venules to the pathogenic vasoconstrictor ET-1. The salient findings of the present study show that ET-1 elicits mostly ET~A~R-dependent constriction of human retinal venules, with enhanced vasoconstriction during acute exposure to a diabetic level of high glucose.

An earlier study has shown that the intravenous administration of ET-1 in healthy human subjects decreases blood velocity and flow in large retinal veins without altering their diameter,[@bib32] but it could not rule out whether ET-1 directly influenced the diameter of the small retinal venules. Based on a previous evaluation of porcine retinal venular reactivity in vitro to various vasoconstrictors, ET-1 elicits the most potent response compared with the thromboxane analog U46619 and norepinephrine.[@bib21] In the present study, we evaluated for the first time the direct vasomotor response of isolated and pressurized human retinal venules to ET-1. These vessels had an average maximum diameter of 68 µm, which was slightly smaller than the porcine retinal venules (about 100 µm) examined in the current study. Both human and porcine retinal venules developed comparable basal tone (constricted to about 88%--92% of the maximum diameter). Furthermore, human and porcine retinal venules displayed comparable vasoconstrictor responsiveness to ET-1 ([Fig. 2](#fig2){ref-type="fig"}B), with a threshold concentration of about 1 pM and a maximum constriction to about 50% of their resting diameters at the highest concentration tested (1 nM). These concentrations are within the range reported for vitreous fluid (picomolar range) in both experimental and clinical models[@bib5]^,^[@bib21]^,^[@bib33] and the estimated level at the local microvasculature (nanomolar range),[@bib34] which support the pathophysiologic relevance of these ET-1--induced vasoconstrictor responses. Although a low number of male human vessels was available for the present study, we did not find statistical significance in ET-1--induced constriction of retinal venules between male (*n* = 3) and female (*n* = 3) pigs.

The retinal arteriolar microcirculation contains two major receptor subtypes, ET~A~R and ET~B~R, for ET-1 binding and alteration of vasomotor tone.[@bib7]^,^[@bib30] In the present study, the ET-1--elicited constrictions of small human and porcine retinal venules appeared to be mediated solely by ET~A~R, because selective ET~A~R antagonist BQ123 (1 µM) eliminated the vasoconstriction ([Fig. 3](#fig3){ref-type="fig"}). This finding is consistent with our previous report that ET~B~Rs do not play a role in the constriction of large porcine retinal venules (averaged maximum diameter of about 133 µm) to ET-1.[@bib20] The nominal vasomotor influence of ET~B~R in retinal venules was further supported by the inability of ET~B~R agonist sarafotoxin to alter resting diameter of porcine retinal venules.[@bib20] By contrast, porcine retinal arterioles constricted in response to sarafotoxin, which was abolished by selective ET~B~R antagonist BQ788 (0.1 µM)[@bib35] and unaffected by BQ123 (1 µM).[@bib30] The 1 µM concentration of BQ123 used in the present study is in the range that has been shown to selectively prevent ET-1 binding to ET~A~Rs.[@bib36] The median inhibitory concentration for BQ123 to inhibit the binding of ET-1 to ET~A~Rs in porcine aortic vascular smooth muscle cells and to ET~B~Rs in human glioblastoma cells and porcine cerebellar membranes was 7.3 nM and 9.7 to 18 µM, respectively.[@bib36] Therefore, our current findings demonstrate for the first time in small human retinal venules that ET~A~R is the dominant receptor subtype responsible for the vasoconstriction evoked by the physiologic and pathologic levels of ET-1. Taken together, the ability of human and porcine retinal venules to develop significant basal tone and to respond to ET-1 via activation of ET~A~R with robust vasoconstriction supports the potential role of these vessels in the regulation of flow resistance, local pressure, and fluid exchange in the retinal microcirculation.

The retina is capable of synthesis and release of ET-1 via endothelin-converting enzyme-1, which was recently found to be functionally expressed in the porcine retinal microcirculation[@bib30]^,^[@bib37] and in bovine[@bib38] and human[@bib39] retinal tissues. It is reasonable to surmise that ET-1 may contribute to the retinal complications of diabetes, because multiple clinical studies have reported increased plasma[@bib40] and vitreous[@bib12] levels of ET-1 and decreased retinal blood flow[@bib41] in patients with diabetes. Furthermore, we recently detected elevated ET-1 protein levels in the vitreous humor of pigs after 2 weeks of hyperglycemia.[@bib21] Interestingly, hyperglycemia, either in vitro or in vivo, appears to enhance the constriction of large retinal venules to general vasoconstrictors, such as norepinephrine and thromboxane analog, with the most pronounced effect on ET-1.[@bib21] It is conceivable that elevated levels of ET-1 in the vitreous in diabetes may exert a local influence not only on venules, but also on arterioles and pericyte-containing capillaries in the retinal microcirculation. However, previous studies have shown that hyperglycemia decreases the ET-1--induced contraction of bovine retinal pericytes in vitro.[@bib42] Although we have shown that both in vitro and in vivo hyperglycemia impair endothelium-dependent nitric oxide-mediated dilation of isolated porcine retinal arterioles,[@bib15]^,^[@bib16] up to 12 weeks of in vivo hyperglycemia does not alter the vasoconstrictor responsiveness of these vessels to ET-1.[@bib16] These earlier findings in retinal arterioles and our current results with retinal venules suggest a differential impact of hyperglycemia/diabetes on the vasoconstrictor function at different segments of vessels in the retinal microcirculation. Moreover, hyperglycemia during diabetes may promote the increased local retinal production of ET-1[@bib21] that could preferentially enhance retinal venular constriction. To support the clinical relevance of this idea to the human retinal microcirculation, the present investigation showed for the first time that ET-1--induced constriction of retinal venules from patients without diabetes was augmented by a high level of glucose in the lumen ([Fig. 4](#fig4){ref-type="fig"}). Similar results were observed for the porcine retinal venules exposed to high glucose and the enhanced constriction of these vessels to a pathophysiologic level of 0.1 nM ET-1 was abolished in the presence of ET~A~R blockade ([Fig. 5](#fig5){ref-type="fig"}). Future studies will assess the influence of high glucose on the ET-1--induced activation of ET~A~R in human retinal venules. The current findings also suggest the potential promotion of retinal complications by altering reactivity of these microvessels with decreased retinal perfusion and evoked tissue edema if the compensatory or defense mechanisms against microvascular disturbance (e.g., blood flow dysregulation and disarray of tissue fluid homeostasis) are compromised in diabetes before the morphologic changes of diabetic retinopathy. The progression to severe diabetic retinopathy is associated with widening of large retinal venules (\>120 µm),[@bib43]^,^[@bib44] possibly related to development of retinal arteriole to venule shunts that bypass the diminished perfusion of capillaries.[@bib45]^,^[@bib46] The impact of different stages of diabetes on the diameter of small retinal venules in humans, as evaluated in the present study, remain to be determined. Nonetheless, our findings herein provide new insight that early exposure to hyperglycemia in diabetes may influence vasomotor function of human retinal venules. Additional investigations are needed to address the potential alteration of signaling mechanisms, such as the reverse-mode sodium--calcium exchanger, contributing to the augmented ET-1--induced constriction of human retinal venules during hyperglycemia, as we have observed in porcine retinal venules.[@bib21]

A potential limitation of the present study is the inability to determine whether melanoma or cardiovascular disease influences the results. Four of the five patients had documented risk factors for cardiovascular disease (i.e., diabetes, hypertension, and hyperlipidemia) and were being treated with appropriate medications. A small sample size for the different combinations of cardiovascular disease risk and pharmacotherapy precludes the discovery of statistically significant differences based on these factors. It is important to note that access to human retinal tissue after enucleation is rare with only about one or two samples per year from our institution. Furthermore, the ability to obtain the retinal tissue within about 1 to 2 hours after enucleation has been critical to maintain venule viability for vasoreactivity studies. We did not have sufficient retinal tissue and vessels from patients with diabetes to investigate the effect of high glucose on the responsiveness to ET-1. However, their vessels seemed to constrict to ET-1 comparably with the patients without diabetes during normal glucose exposure. This finding is not surprising, because these patients did not have retinal complications (i.e., clinically apparent diabetic retinopathy) and the glucose level was controlled by the noninsulin antidiabetic drugs. Moreover, only one ET-1 response curve could be generated in an individual vessel because the constriction is sustained after washing out ET-1, so the control and treatment (BQ123 or high glucose) cannot be performed and compared in the same vessel. Nonetheless, our current findings unequivocally show that ET-1 causes constriction of retinal venules from patients without type 1 or type 2 diabetes, with an augmented response after exposure to high glucose in vitro.

In summary, we found that isolated human retinal venules develop stable basal tone and constrict to ET-1 by activation of ET~A~Rs. Our present studies revealed similarities in the ET-1--induced constriction of human and porcine retinal venules, which corroborates the pig as a relevant animal model for the study of vasomotor function in the retinal microcirculation. We also demonstrated that hyperglycemia does not influence basal tone, but rather enhances ET-1--induced constriction of small human and porcine retinal venules. Our findings provide the initial insight into the direct impact of hyperglycemia on the reactivity of small human retinal venules to ET-1, which may suggest a key therapeutic vascular target for retinal complications, especially in patients with diabetes or other retinal vascular diseases[@bib47]^,^[@bib48] related to elevated ET-1.
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